Technology evaluation: MRA, Chugai

Ding, C and Jones, G (2003) Technology evaluation: MRA, Chugai. Current Opinion in Molecular Therapeutics, 5 (1). pp. 64-69. ISSN 1464-8431

Preview

PDF - Requires a PDF viewer
51Kb

Official URL: http://www.biomedcentral.com/1464-8431/5?issue=1

Abstract

Chugai, the Japanese subsidiary of Roche, is developing a humanized anti-interleukin (IL)-6 receptor monoclonal antibody MRA for the potential treatment of multiple myeloma, rheumatoid arthritis, Crohn's disease and other IL-6-related disorders. MRA is currently undergoing phase II clinical trials for these indications.

Item Type:	Article
ID Code:	3552
Deposited By:	Dr Changhai / C Ding
Deposited On:	28 Mar 2008 11:57
Last Modified:	18 Jul 2008 20:41
ePrint Statistics:	View statistics for this ePrint

Repository Staff Only: item control page